Villers-lès-Nancy,
PRESS RELEASE
H1 2020 Results
- A resilient business model:
- Revenue: +1.4% to €77.93m.
- Operating Profit: +8.4% to €20.73m.
- Group market positions bolstered by significant acquisitions in H1.
- Employees actively engaged in supporting healthcare professionals during the crisis.
- Outlook:
- Meeting the challenges of tomorrow more than ever offering promising market opportunities for the Group.
- Strong recovery in business since early June.
- Group targets for H2 maintained, particularly for earnings.
€m | H1 2020 | H1 2019 | Change |
Revenue | 77.93 | 76.88 | +1.4% |
Operating Profit | 20.73 | 18.65 | +8.4% |
Net Profit from Continuing Operations | 13.50 | 13.18 | * +2.3% |
Net Profit | 13.50 | 14.59 | * -7.5% |
*
********
Ø Results at
Within the context of a health crisis of unprecedented dimensions,
Operating Profit of the Group grew 8.4% to €20.73m at
- Operating Profit for the Pharmacy - Europe Solutions Division amounted to €13.29m (+2.8%). The strong rebound in orders of the Pharmacy France Business Unit beginning in June partially offset the slower start-up of operations by the Pharmacy Belux and Italy Business Units, two countries remaining severely impacted by the health crisis.
- Operating Profit of the Health and Social Care Facilities Solutions Division was €4.33m, with strong growth of 25.5%. Boosted by the integration of
MALTA BELGIUM and PANDALAB, this Division also benefited from innovative development projects linked to other Group Divisions within the framework of the Digital Healthcare Platform. - Operating Profit of the e-
Health Solutions and Fintech Divisions amounted to €3.12m, up 37.4%, on the strength of a positive product mix (recurrent e-Connect business and Telemedicine projects). These Divisions are continuing to invest in R&D to support their international ambitions (notably for NOVIACARE).
Net Profit on that basis amounted to €13.50m (-7.5%) and Net Profit Attributable to Equity Holders of the Parent to €12.63m (-7.8%). At
Ø Consolidated balance sheet highlights
At
Equity attributable to the equity holders of the Parent at
- H1 2020 operating highlights
- Creation of
MALTA BELGIUM . The Health and Social Care Facilities (HSCF) Solutions Division is continuing to develop inEurope by acquiring the activities for developing software solutions for nursing homes and specialised establishments of the Belgian company, CARE SOLUTIONS. This acquisition provides access to more than 630 nursing homes inBelgium out of the country's total of 1,540 retirement homes. In conjunction with the acquisition of CARE SOLUTIONS’ activities,MALTA INFORMATIQUE signed a strategic partnership with Colisée Group,Europe's fourth-largest provider of solutions for elderly care and well-being.
- Acquisition of a majority stake in PANDALAB. The HSCF Solutions Division has in this way strengthened its offering to provide a better coordination of the patient care pathway by means of this multi-functional platform integrating secure, confidential and instantaneous messaging capabilities between healthcare professionals. This solution is also promising in terms of its potential for strong synergies with all the
Pharmagest Group businesses and contributing to a significant advance in the Group's strategy to build a unique ecosystem inFrance andEurope and the deployment of its Digital Healthcare Platform.
- Creation of
§ Acquisition of ASCA INFORMATIQUE. By this operation,
§ AXIGATE was selected by RESAH (Réseau des Acheteurs Hospitaliers), the French hospital purchasing network, to address the needs of regional hospital groups in monitoring patient pathways. As a French leader in the Hospital Information Systems (HIS) sector, AXIGATE provides an innovative solution for Electronic Medical Records addressing multi-establishment information needs and covering the inter-and intra-hospital patient pathway. AXIGATE’s information system addresses the needs of all healthcare stakeholders: hospitals, regional hospital groups, senior homes, hospital-at-home programmes and home-based nursing services but also private practice physicians.
§
§ Pharmagest Group R&D teams rank number one in
§
Ø Significant events occurring after
AXIGATE announces the signature of agreement with 3 new hospitals:
- The Armor Regional Hospital Network: after laying the foundations for a territorial information system in
November 2019 , and launching the pilot service inJanuary 2020 , the Armor Regional Hospital Network rolled out the AXIGATE EMR system at the territory’s different establishments. Its functional scope will be extended in the coming months with the deployment of the medication pathway, the programme for medicalization of information systems, the obstetric file and emergency services.
- The Gisors and Andelys Hospital Centres of the Eure-Seine Regional Hospital Network: the Gisors hospital (464 hospital beds) and the Saint Jacques hospital in Andelys (230 beds for medium and long-term stays) of the Eure-Seine Regional Hospital Network selected the AXIGATE EMR to equip a total of 7 hospitals of the department around the support structure of Evreux.
§ Arles Hospital Centre: AXIGATE was selected by the Arles hospital (650 hospital beds) for the digitization of its care processes. This initiative, which follows that of the
Ø H2 2020 outlook
After the very robust recovery in commercial activity in June, continuing growth momentum has set the stage for a strong rebound in revenue in the 2020 second half. On that basis, the Group is confident in the outlook for growth and profitability for the second half.
In addition, Pharmagest Group’s gross cash position ensures it has the resources to pursue market opportunities that may arise in order to meet the challenges of tomorrow.
In the same way, the Group intends to accelerate the deployment of new solutions to support all activities of the healthcare universe: pharmacies, senior homes, home-based nursing services, hospital-at-home programmes and also office-based private practitioners.
Finally, driven by the development of the Digital Healthcare Platform,
This initiative strengthens Pharmagest Group’s position as an innovative industrial stakeholder in the service of health, capable of structuring and delivering technological solutions that are essential for the healthcare offering and its coordination across the office-based private practice and hospital pathways, as described in the French government healthcare plan (“Ma santé 2022”).
Financial calendar
- Participation in the MidCap Event in
Paris on 19 and20 October 2020 . - Publication of Q3 2020 sales:
18 November 2020 (after the close of trading) - Publication of FY 2020 annual sales:
4 February 2021 (after the close of trading).
About
With more than 1,100 employees and “Citizens in the Service of Health and Well-Being”,
As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals,
Listed on Euronext Paris™ - Compartment B
Indices: CAC® SMALL and CAC ® All-Tradable by inclusion
Eligible for the Long-Only Deferred Settlement Service (SRD)
ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: - PMGI FP
The Group is included in the Gaïa-Index 2019 comprised of socially responsible mid-caps and was recently included in the “European Rising Tech” label recognising the top-performing SMEs listed on the Euronext markets of
For all the latest news go to www.pharmagest.com
Follow
CONTACTS
Analyst and Investor Relations:
Chief Administrative and Financial Officer : Jean-Yves SAMSON
Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@lacooperativewelcoop.com
Media Relations:
FIN’EXTENSO – Isabelle APRILE
Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr
Attachment
- PHARMAGEST_PRESSRELEASE_20200925_H1 RESULTS 2020_
© OMX, source